Dear Cancer Institute NSW,

An application to provide a poster and oral presentation for the 2017 Innovation in Cancer Treatment and Care to be held on 14th September 2017 has been rejected without a full explanation.

It is hard to believe that there was not room for one additional poster!.
Yes there may not have been time for one more 15 minute oral presentation
What other FActors and Considerations were involved in the rejection ?
Perhaps they were too much of a challenge for current cancer treatment thinking and the Pharmaceutical Industry .
Currently an Orphan Drug Designation Application has been lodged with the Therapeutic Goods Administration for the Patented Novel acid stabilised Omeprazole Formulation NACO which provides a very innovative approach to cancer treatment.

Yours faithfully,

John A. Hackett
Director
JON Pty Ltd
.

2017 Innovations in Cancer Treatment and Care Conference
Oral Presentation 15 Minutes
Abstract Title: Reduction in Cancer Mortality , Toxicity and Cost of Treatments by Re-Purposing Generic Pharmaceuticals

John A. Hackett BSc(Tech) MRACI CChem.
Research Director
JON Pty. Ltd

2017 Innovations in Cancer Treatment and Care Conference
Oral Presentation 15 Minutes
Abstract Title: Reduction in Cancer Mortality , Toxicity and Cost of Treatments by Re-Purposing Generic Pharmaceuticals

John A. Hackett BSc(Tech) MRACI CChem.
Research Director
JON Pty. Ltd

ABSTRACT
New cancer treatments are often driven by the pursuit of corporate profits rather than development of more cost effective treatments. Re-Purposing of low toxicity, low cost generic pharmaceuticals in the treatment of cancers has received sporadic attention and funding in recent times. By utilising a focused reverse engineering process approach significant progress can be made in this area.
Low Toxicity Generics often show promise when used for in vitro and in vivo cancer trials but may not be so effective in human trials.
There are many challenges in translating these results to humans which need to be resolved. One major challenge is the Tumor microenvironment .
Tumor microenvironment acidity can block drug transport and induce drug breakdown. The more aggressive cancer mutations have higher levels of acidity in their microenvironment leading to drug resistance. Tumors are Heterogenous with many mutations having various levels of acidity in their microenvironments.
A reduction in tumor microenvironment acidity can increase the effectiveness of some generic pharmaceuticals for cancer treatment.
Metformin is a good example if used in combination with an acid stabilised Proton Pump Inhibitor such as NACO
This combination example meets the goals of :-
“ Reduction in Cancer Mortality , Toxicity and Cost of Treatments by Re-Purposing Generic Pharmaceuticals”